Evidence map›Paper›PMID 27612553›Full record

ReviewTrends in cardiovascular medicine2017

Impact of empagliflozin in patients with diabetes and heart failure.

David Pham, Natalia De Albuquerque Rocha, Darren K McGuire, Ian J Neeland

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Trends in cardiovascular medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Observational
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Morbid Obesity as a Therapeutic Target for Heart Failure.Current treatment options in cardiovascular medicine · 2019
    Review
  11. Review
  12. Review
  13. Review
  14. Metabolic Origins of Heart Failure.JACC. Basic to translational science · 2017
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

David PhamDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd Dallas, TX 75390-8830.
Natalia De Albuquerque RochaDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
Darren K McGuireDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd Dallas, TX 75390-8830; Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX.
Ian J NeelandDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd Dallas, TX 75390-8830. Electronic address: ian.neeland@utsouthwestern.edu.

Funding

Visceral Adiposity and Diabetes: Translating Form to Function Using ImagingK23DK106520 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI NEELAND, IAN JASON · 2015 to 2019
$776k
NIDDK NIH HHS K23 DK106520
6 · The paper itself

Abstract

Heart failure (HF) is a common disease with increased risk for mortality and morbidity among patients with type 2 diabetes mellitus (T2DM). Optimal glycemic control in this patient population is challenging as many available therapies can potentially exacerbate symptoms of HF. Empagliflozin is one in a novel class of agents, the sodium glucose co-transporter 2 (SGLT2) inhibitors, that lowers blood glucose by increasing urinary glucose excretion and improves glycemic control and lowers body weight and blood pressure. In the recent EMPA-REG OUTCOME trial, empagliflozin was shown to improve cardiovascular outcomes in patients with T2DM and established cardiovascular risk where it reduced HF hospitalizations and cardiovascular death, with a consistent benefit among patients both with and without baseline HF. Here, we review the empagliflozin data on HF outcomes and discuss potential mechanisms for its benefits in HF with a focus on the potentially significant impact that empagliflozin may have on the care of patients with T2DM and HF in the future.

Indexed as

AnimalsBenzhydryl CompoundsBlood GlucoseDiabetes Mellitus, Type 2GlucosidesHeart FailureHospitalizationHumansHypoglycemic AgentsRisk AssessmentRisk FactorsSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsTreatment OutcomeBenzhydryl CompoundsBlood GlucoseempagliflozinGlucosidesHypoglycemic AgentsSLC5A2 protein, humanSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsEmpagliflozinHeart failureSGLT2 inhibitorType 2 diabetes mellitus

Identifiers

PMID27612553
PMCPMC5253088

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.